<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>SLE patients with identified and probable APS compared with those having no APS have been found to have more significant endothelial function <z:e sem="disease" ids="C0007273" disease_type="Disease or Syndrome" abbrv="">disorders, carotid artery</z:e> intima-media thickness (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e>) and intensity of atherosclerotic vascular impairment </plain></SENT>
<SENT sid="1" pm="."><plain>At the same time antibody level to beta-2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> 1 reliably correlates (r= 0.39, 0.38, 0.33) with <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> specificity and carotic artery atherosclerotic impairment </plain></SENT>
<SENT sid="2" pm="."><plain>The development of structural and functional myocardial defect in SLE patients less depends on APS presence </plain></SENT>
<SENT sid="3" pm="."><plain>Persons with high antibody level to beta-2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> 1 were found to have oftener a left ventricular myocardial hyperthrophy and impairment of diastolic heart function than patients with no antibodies to beta-2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> 1 </plain></SENT>
</text></document>